Modality
Small Molecule
MOA
IL-17i
Target
Cl18.2
Pathway
Notch
MDDMDS
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
→ Aug 2027
Phase 1Current
NCT08461111
2,528 pts·MDD
2019-10→2025-01·Completed
NCT07148694
691 pts·MDD
2023-01→2027-08·Active
3,219 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-181.2y agoInterim· MDD
2027-08-211.4y awayInterim· MDD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2025-01-18 · 1.2y ago
MDD
Interim
2027-08-21 · 1.4y away
MDD
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 |